Skip to main content
Michael S. Kay

Michael S. Kay, MD, PhD

Languages spoken: English

Academic Information

Departments Primary - Biochemistry

Academic Office Information

kay@biochem.utah.edu

Research Interests

  • Virology
  • Protein Design
  • Drug Design
  • Peptides
  • Protein Chemistry
  • Chemical Biology

Education History

Postdoctoral Fellowship Massachusetts Institute of Technology
Postdoctoral Fellow
Stanford University
PhD
Professional Medical Stanford University
MD
Cornell University
BA

Selected Publications

Journal Article

  1. Clinton TR, Weinstock MT, Jacobsen MT, Szabo-Fresnais N, Pandya MJ, Whitby FG, Herbert AS, Prugar LI, McKinnon R, Hill CP, Welch BD, Dye JM, Eckert DM, Kay MS (2015). Design and characterization of ebolavirus GP prehairpin intermediate mimics as drug targets. Protein Sci, 24(4), 446-63.
  2. Weinstock MT, Jacobsen MT, Kay MS (2014). Synthesis and folding of a mirror-image enzyme reveals ambidextrous chaperone activity. Proc Natl Acad Sci U S A, 111(32), 11679-84.
  3. Mesquita PM, Srinivasan P, Johnson TJ, Rastogi R, Evans-Strickfaden T, Kay MS, Buckheit KW, Buckheit RW Jr, Smith JM, Kiser PF, Herold BC (2013). Novel preclinical models of topical PrEP pharmacodynamics provide rationale for combination of drugs with complementary properties. Retrovirology, 10(1), 113.
  4. Pang HB, Hevroni L, Kol N, Eckert DM, Tsvitov M, Kay MS, Rousso I (2013). Virion stiffness regulates immature HIV-1 entry. Retrovirology, 10, 4.
  5. Francis JN, Redman JS, Eckert DM, Kay MS (2012). Design of a modular tetrameric scaffold for the synthesis of membrane-localized D-peptide inhibitors of HIV-1 entry. Bioconjug Chem, 23(6), 1252-8.
  6. Denton PW, Othieno F, Martinez-Torres F, Zou W, Krisko JF, Fleming E, Zein S, Powell DA, Wahl A, Kwak YT, Welch BD, Kay MS, Payne DA, Gallay P, Appella E, Estes JD, Lu M, Garcia JV (2011). One percent tenofovir applied topically to humanized BLT mice and used according to the CAPRISA 004 experimental design demonstrates partial protection from vaginal HIV infection, validating the BLT model for evaluation of new microbicide candidates. J Virol, 85(15), 7582-93.

Patent

  1. Jacobsen, Michael J, Erickson, Patrick W, Kay, Michael S (2019). SYSTEMS AND METHODS FOR OPTIMIZING CHEMICAL PROTEIN SYNTHESIS DESIGN. U.S. Patent No. application #2018/033865. Washington, D.C.:U.S. Patent and Trademark Office.
  2. WELCH, BRETT D, KAY, MICHAEL S, ECKERT, DEBRA MUIR, MCKINNON, RENA, JACOBSEN, MICHAEL THOMAS (2018). COMPOSITIONS AND METHODS RELATED TO INHIBITION OF RESPIRATORY SYNCYTIAL VIRUS ENTRY. U.S. Patent No. application #20180280520. Washington, D.C.:U.S. Patent and Trademark Office.
  3. CLINTON, Tracy R, JACOBSEN, Michael Thomas, WEINSTOCK, Matthew T, WELCH, Brett D, ECKERT, Debra Muir, KAY Michael S. (2017). EBOLAVIRUS PRE-HAIRPIN INTERMEDIATE MIMICS AND METHODS OF USE. U.S. Patent No. application #20170247418. Washington, D.C.:U.S. Patent and Trademark Office.
  4. Welch BW, Kay MS (2016). Methods and Compositions Related to Inhibition of Viral Entry. U.S. Patent No. 9,381,226. Washington, D.C.:U.S. Patent and Trademark Office.
  5. Francis JN, Kay MS (2011). Methods and Compositions Related to Inhibition of Viral Entry. U.S. Patent No. Provisional Application No. 61/468,094. Washington, D.C.:U.S. Patent and Trademark Office.
  6. Welch BW, Kay MS (2007). Designed antigens to elicit neutralizing antibodies against sterically restricted antigen and method of using same. U.S. Patent No. Application # 20070122429. Washington, D.C.:U.S. Patent and Trademark Office.
  7. Root MJ, Kay MS, Chan DC, Kim PS (2006). Five Helix Protein. U.S. Patent No. 7,053,179, 7,504,224, 8,058,012. Washington, D.C.:U.S. Patent and Trademark Office.